Vol. 23 No. 2 (2025): Blood Transfusion 2-2025 (March-April)
Full Issue
pdf
Review
-
Noninvasive fetal blood group antigen genotyping: Noninvasive fetal blood group antigen genotyping
-
Comprehensive analysis of parvovirus B19 infection in blood donors: epidemiological trend and implications for transfusion safety and management strategies in Italy: Epidemiology and transfusion safety of B19V in donors
Original article
-
Rh disease in Mexico: evaluating regional and institutional differences in treatment availability and disease management: Rh disease awareness in Mexico
-
How do we transfuse children in Italy? Results of a national survey: National survey on pediatric transfusions in Italy
-
Red blood cell transfusion in patients undergoing elective primary glioblastoma resection: RBC transfusion in glioblastoma patients
-
Quality and stability studies of red blood cell concentrates from umbilical cord blood compared to their adult counterparts: CB-RBC quality and stability studies compared to adult RBC
-
Donor-specific anti-HLA antibodies (DSAs) in patients undergoing allogeneic hematopoietic stem cell transplantation from mismatched donors on behalf of GITMO and AIBT: Anti-HLA and DSA management in Italian Transplant Programs
Brief report
-
The -72G>A nucleotide substitution impairs transcription of the ABO gene via reduction of promoter activity: Substitution mutation leads to the “3” subgroup phenotype
-
CD36 antibodies in isoimmunised African-origin pregnant women: three years experience in Spain: CD36 antibodies in isoimmunised African-origin pregnant women
Letter to the Editor
-
Cryoprecipitate should not be the essential medicine recommended by the WHO to treat haemophilia: Factor VIII concentrate rather than cryoprecipitate for Haemophilia
-
Recommending defunct therapies is a safety risk for hemophilia: Therapies and safety risks in haemophilia
-
Response to comments on inclusion of cryoprecipitate, pathogen-reduced on the WHO model lists of essential medicines for adults and children: a call for action: Responses to comments on Cryo-PR listing on the WHO EML
Announcements
Winter Closure
The Editorial Office will be closed from December 31 to January 7, 2026.
Season’s greetings to all our readers, authors, and reviewers.
Read moreSIMTI 2026
46° Convegno Nazionale di Studi di Medicina Trasfusionale - Abstract Book (in Italian)
Read moreSETS 2026
35° Congreso de la Sociedad Española de Transfusión Sanguínea y Terapia Celular - SETS - Abstract Book (in Spanish), is online (https://www.bloodtransfusion.it/bt/issue/view/81).Madrid, 4-6 June 2026.
Read moreEditorial Office Closure Notice
Please note that the BT Editorial Office will be closed until August 26, 2026.
During this period, responses to inquiries and the processing of manuscripts may be delayed. All editorial activities will resume as usual after this date.
Thank you for your understanding.
Best regards,
BT Editorial Office
Read more
Impact Factor 2025
We are pleased to announce that Blood Transfusion has achieved a 2025 Impact Factor of 2.7.
Read more